Nanovibronix Stock Story

NAOV -  USA Stock  

USD 2.04  0.05  2.39%

As many investors are getting excited about healthcare space, it is fair to focus on Nanovibronix. What exactly are Nanovibronix shareholders getting in August? Is Nanovibronix valuation sustainable? Here I will cover a perspective on valuation of Nanovibronix to give you a better outlook on taking a position in this stock.
Published over two months ago
View all stories for Nanovibronix | View All Stories
Is Nanovibronix (NASDAQ:NAOV) ready for a correction?
Nanovibronix currently holds 25 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the firm is not taking enough advantage from borrowing. This firm has a current ratio of 9.35, suggesting that it is liquid enough and is able to pay its financial obligations when due.
We provide investment recommendation to complement the last-minute expert consensus on Nanovibronix. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Nanovibronix using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Nanovibronix based exclusively on its fundamental and basic technical indicators. By analyzing Nanovibronix's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Nanovibronix's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nanovibronix. We calculate exposure to Nanovibronix's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Nanovibronix's related companies.

Nanovibronix Investment Alerts

Nanovibronix investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Nanovibronix performance across your portfolios.Please check all investment alerts for Nanovibronix

Nanovibronix Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Nanovibronix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nanovibronix competition to find correlations between indicators driving the intrinsic value of Nanovibronix.

How Nanovibronix utilizes its cash?

To perform a cash flow analysis of Nanovibronix, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Nanovibronix is receiving and how much cash it distributes out in a given period. The Nanovibronix cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Nanovibronix Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Nanovibronix reported Net Cash Flow from Operations of (3.39 Million) in 2020

A Deeper look at Nanovibronix

The company reported the previous year's revenue of 612 K. Net Loss for the year was (8.32 M) with profit before overhead, payroll, taxes, and interest of 214 K.
 2018 2019 2020 2021 (projected)
Revenues USD318 K530 K623 K499.39 K
Revenues318 K530 K623 K499.39 K

Margins Breakdown

Nanovibronix profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Nanovibronix itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Nanovibronix profit margins.
EBITDA Margin(7.2)
Gross Margin0.42
Profit Margin(7.49)


Nanovibronix Average Assets is increasing over the last 8 years. The latest value of Nanovibronix Average Assets is 3,001,877. Also, Nanovibronix Earnings before Tax is decreasing over the last 8 years. The previous year's value of Nanovibronix Earnings before Tax was -4,650,263.

Our perspective of the latest Nanovibronix climb

Latest expected short fall is at -14.06.
As of the 24th of July, Nanovibronix secures the Risk Adjusted Performance of 0.0981, mean deviation of 8.64, and Downside Deviation of 4.66. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nanovibronix, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Nanovibronix, which can be compared to its peers in the industry. Please verify Nanovibronix standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Nanovibronix is priced some-what accurately, providing market reflects its recent price of 2.61 per share. Please also check out Nanovibronix total risk alpha, which is currently at 2.27 to check the company can sustain itself at a future point.

Our Final Perspective on Nanovibronix

While many of the other players under the medical devices industry are still a bit expensive, Nanovibronix may offer a potential longer-term growth to sophisticated investors. On the whole, as of the 24th of July 2021, we believe that at this point, Nanovibronix is abnormally volatile with below average odds of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our primary 90 days buy-hold-sell recommendation on the venture is Strong Buy.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Nanovibronix. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com